EXO1 as a potential biomarker for prognosis, immune infiltration, and immunotherapy in pan-cancer analysis

被引:0
|
作者
Wang, Jikang [1 ,2 ,3 ]
Wang, Fubo [4 ]
Huang, Haoxuan [4 ]
机构
[1] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Peoples R China
[2] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Nanning 530021, Peoples R China
[3] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Peoples R China
[4] Guangxi Med Univ, Ctr Genom & Personalized Med, Guangxi Collaborat Innovat Ctr Genom & Personalize, Guangxi Key Lab Genom & Personalized Med, Nanning 530021, Guangxi, Peoples R China
关键词
EXO1; Prognosis; Immune infiltration; Immunological biomarker; Immunotherapy; REPAIR; EXONUCLEASE-1;
D O I
10.1007/s10142-025-01586-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Human EXO1 is a 5' -> 3' exonuclease that plays a critical role in regulating cell cycle checkpoints, maintaining replication forks and participating in post-replication DNA repair pathways. Previous studies have highlighted the importance of EXO1 in cancers such as liver and breast cancer. However, there is a gap in the comprehensive analysis of EXO1 in a wide range of cancers, and its precise role in cancer patient prognosis and immune response remains unclear. This study aims to systematically investigate the potential associations between EXO1, immune infiltration and prognostic value in different cancer types and to gain a deeper understanding of its mechanisms of action.We conducted a comprehensive investigation into the overarching role of EXO1 across various cancers by utilizing multiple databases. Our analysis encompassed scrutinizing EXO1 expression and evaluating its correlation with clinical survival, immune checkpoints, Tumor Stemness Score, Prognostic Value, immunomodulators, genomic profiles, immunological characteristics, immunotherapy, and functional enrichment. EXO1 is expressed in various normal tissues and at significantly higher levels in most tumors compared to non-tumor tissues. High EXO1 expression is associated with poor prognosis in certain cancers. Genetic mutations and RNA modifications of EXO1 were also investigated, as well as its correlation with tumor immunity and genomic stability. We investigated the potential role of EXO1 in immunotherapy and identified differing drug responses based on EXO1 expression levels in Skin Cutaneous Melanoma (SKCM), which holds promise for personalized treatment. Furthermore, we analyzed EXO1-related genes and pathways, revealing its potential involvement in crucial biological processes such as DNA repair and cell cycle regulation. These findings provide a comprehensive understanding of the role of EXO1 in cancer initiation and progression, offering valuable insights for personalized cancer therapy and precision medicine. This study highlights the diverse functions of EXO1 in cancer, including its involvement in cancer initiation, prognosis, immune regulation, and response to immunotherapy. These findings provide valuable insights into the potential of EXO1 as a biomarker and therapeutic target, as well as its role in determining treatment response in cancer management. This information is crucial for guiding personalized cancer therapy and precision medicine.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker
    Feng, Ziyang
    Chen, Yu
    Cai, Changjing
    Tan, Jun
    Liu, Ping
    Chen, Yihong
    Shen, Hong
    Zeng, Shan
    Han, Ying
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] Potential prognostic biomarker of OSBPL10 in pan-cancer associated with immune infiltration
    Qi, Jiapeng
    Yu, Kun
    Liu, Bei
    Wang, Yan
    Wang, Wei
    An, Ran
    Wang, Chaojun
    Li, Na
    Xu, Dongqian
    Liu, Lin
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [33] Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response
    Tong, Wen
    Wang, Guangyu
    Zhu, Liuyang
    Bai, Yi
    Liu, Zirong
    Yang, Long
    Wu, Hao
    Cui, Tao
    Zhang, Yamin
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 8
  • [34] Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response
    Zheng, Hong
    Wang, Minghao
    Zhang, Shiyu
    Hu, Dongxue
    Yang, Qiaoyun
    Chen, Ming
    Zhang, Xia
    Zhang, Yi
    Dai, Jigang
    Liou, Yih-Cherng
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (14): : 4689 - 4708
  • [35] Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy
    Zhang, Nie
    He, Zhuoying
    Qin, Xuejin
    Han, Ke
    Zhu, Zhengchun
    Zhong, Fei
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [36] Pan-cancer exploration of PNO1: A prospective prognostic biomarker with ties to immune infiltration
    Qin, Yinhui
    Li, Zhen
    Zhang, Xianwei
    Li, Junjun
    Teng, Yuetai
    Zhang, Na
    Zhao, Shengyu
    Kong, Lingfei
    Niu, Weihong
    HELIYON, 2024, 10 (17)
  • [37] Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis
    Wu, Linyong
    Liao, Wei
    Wang, Xiaodong
    Zhao, Yujia
    Pang, Jinshu
    Chen, Yuji
    Yang, Hong
    He, Yun
    BIOENGINEERED, 2021, 12 (02) : 10302 - 10318
  • [38] A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration
    Feng, Yan
    Tao, Fengying
    Qiao, Han
    Tang, Huaping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] PCMT1 confirmed as a pan-cancer immune biomarker and a contributor to breast cancer metastasis
    Liu, Yiqi
    Li, Haobing
    Shen, Xiangyu
    Liu, Ying
    Zhong, Xiaoxiao
    Zhong, Jing
    Cao, Renxian
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (08):
  • [40] CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis
    Ye, Wenrui
    Luo, Cong
    Liu, Fangkun
    Liu, Zhixiong
    Chen, Fenghua
    FRONTIERS IN ONCOLOGY, 2021, 11